Avelumab and Merkel Cell Carcinoma: Understanding Causation and FDA Warnings

From General Health Guidance to Specific Pharmacovigilance

For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screening, and awareness of environmental factors that influence disease. This foundational framework has served populations well, emphasizing broad risk reduction without delving into the specific biological pathways of individual conditions. However, as medical science advances, the same informational rigor must now extend to targeted therapeutic interventions and their unintended consequences. The shift from general health guidance to precise pharmacovigilance is particularly critical when a drug approved for one indication reveals new safety signals in another context. Consider the case of Avelumab, a checkpoint inhibitor initially authorized for Merkel cell carcinoma treatment. Post-marketing surveillance has identified a pattern of adverse events that warrant careful scrutiny, especially in occupational settings where exposure may occur. This transition from population-level health advice to agent-specific risk assessment demands a focused lens: what happens when a biological response modifier, designed for cancer therapy, becomes a potential hazard for workers handling it? The legacy of general health information provides the vocabulary for risk communication, but the pivot to occupational exposure requires acknowledging that even precisely targeted drugs can carry unforeseen liabilities. Thus, the conversation must evolve from “what promotes health” to “what specific exposures demand precaution,” bridging decades of public health messaging with the granular realities of pharmaceutical safety in the workplace.

Avelumab: Mechanism and Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light exposure, leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors do not respond or develop immune-related adverse events due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Causation and FDA Warnings: Evidence and Risk Context

The mechanistic pathway linking avelumab to Merkel cell carcinoma is based on its role as a PD-L1 inhibitor. By blocking PD-L1, avelumab enhances the immune system's ability to recognize and attack cancer cells, including those in MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). This immune checkpoint inhibition can lead to durable responses, but it also carries risks of immune-related adverse events, which are a known consequence of such therapies (https://pubmed.ncbi.nlm.nih.gov/34445385/). The FDA has issued warnings regarding the use of avelumab, including the potential for immune-mediated adverse reactions, though the specific warning for MCC is part of the broader safety profile for immune checkpoint inhibitors. Regarding risk considerations, the adequacy of warnings for avelumab and MCC is supported by clinical trial data and post-marketing surveillance. The JAVELIN Merkel 200 trial provided evidence of efficacy and safety, leading to regulatory approval (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, for patients who are refractory to avelumab, treatment options are limited. Studies have shown that combination therapy with ipilimumab and nivolumab can be effective in avelumab-refractory MCC, with three out of five patients in one study responding to combined therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study of the prospective skin cancer registry ADOREG reported similar findings, highlighting the potential for alternative immune checkpoint combinations in refractory cases (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study also confirmed the use of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC, noting that despite advances, about 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure to avelumab and documented harm, such as lack of response or immune-related adverse events, varies among patients. In clinical trials, responses were assessed over the course of treatment, with objective responses observed in approximately one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). For those who do not respond, progression can occur during or after treatment, as seen in studies where patients were refractory to avelumab and subsequently treated with other agents (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). Immune-related adverse events can occur at any time during treatment, and their management is a key aspect of clinical care. For affected patients, causation-related considerations include the understanding that avelumab is a standard treatment for metastatic MCC, and its use is based on evidence of efficacy. However, not all patients benefit, and the risk of progression or adverse events must be weighed. The availability of alternative therapies, such as ipilimumab plus nivolumab, provides options for those who are refractory to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). Overall, the evidence supports the use of avelumab in MCC while acknowledging the limitations and risks associated with immune checkpoint inhibition.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which avelumab treats Merkel cell carcinoma?

Avelumab is a fully human IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). By blocking PD-L1, it enhances the immune system's ability to recognize and attack cancer cells, including those in Merkel cell carcinoma (https://pubmed.ncbi.nlm.nih.gov/29799096/). This immune checkpoint inhibition can lead to durable responses but also carries risks of immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/).

What are the FDA warnings associated with avelumab?

The FDA has issued warnings regarding the use of avelumab, including the potential for immune-mediated adverse reactions. These warnings are part of the broader safety profile for immune checkpoint inhibitors. The adequacy of these warnings is supported by clinical trial data and post-marketing surveillance (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What treatment options exist for patients who are refractory to avelumab?

For patients refractory to avelumab, combination therapy with ipilimumab and nivolumab has shown efficacy. Studies have reported responses in avelumab-refractory MCC, with three out of five patients responding in one study (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study confirmed similar findings (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, about 50% of patients still progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.